Dominant Dystrophic Epidermolysis Bullosa Overview

Save information for later
Sign Up

Learn About Dominant Dystrophic Epidermolysis Bullosa

What is the definition of Dominant Dystrophic Epidermolysis Bullosa?
Dominant dystrophic epidermolysis bullosa (DDEB) is a type of epidermolysis bullosa (EB), which is a group of rare inherited conditions in which the skin blisters extremely easily. DDEB is one of the milder forms of EB, although the severity is variable. Blisters may be present at birth, but typically appear during early childhood; occasionally they do not develop until later in life. Blisters often become more numerous and tend to occur over vulnerable sites such as knees, ankles, elbows and knuckles. In adulthood, they usually become less frequent and scars fade. Other signs and symptoms of DDEB may include dystrophic or absent nails, constipation, dental caries and swallowing problems. It is caused by genetic changes in the COL7A1 gene and is inherited in an autosomal dominant manner.
What are the alternative names for Dominant Dystrophic Epidermolysis Bullosa?
  • Dominant dystrophic epidermolysis bullosa
  • Autosomal dominant dystrophic epidermolysis bullosa, Pasini and Cockayne-Touraine types
  • DDEB, Pasini and Cockayne-Touraine types
  • DDEB, generalized
  • DDEB-gen
  • Dominant dystrophic epidermolysis bullosa, generalized
  • Dystrophic epidermolysis bullosa, autosomal dominant
  • Epidermolysis bullosa dystrophica, Cockayne-Touraine type (formerly)
  • Epidermolysis bullosa dystrophica, Pasini type (formerly)
  • Epidermolysis bullosa dystrophica, autosomal dominant
  • Generalized dominant dystrophic epidermolysis bullosa
Who are the top Dominant Dystrophic Epidermolysis Bullosa Local Doctors?
Dr. Rajiv K. Nathoo
Dermatology
Dr. Rajiv K. Nathoo
Dermatology

Sun State Dermatology

430 Lake Howell Rd, 
Maitland, FL 
 (36.4 mi)
407-636-3113
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Rajiv Nathoo is a Dermatologist in Maitland, Florida. Dr. Nathoo and is rated as an Experienced provider by MediFind in the treatment of Dominant Dystrophic Epidermolysis Bullosa. His top areas of expertise are Muir-Torre Syndrome, Grover's Disease, Bullae, and Neurocutaneous Melanosis. Dr. Nathoo is currently accepting new patients.

Dr. Michael G. Foss
Dermatology
Dr. Michael G. Foss
Dermatology

Luminary Dermatology PA

2101 61st St W, 
Bradenton, FL 
 (78.1 mi)
941-926-6553
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Michael Foss is a Dermatologist in Bradenton, Florida. Dr. Foss and is rated as an Experienced provider by MediFind in the treatment of Dominant Dystrophic Epidermolysis Bullosa. His top areas of expertise are Erythroderma, Exfoliative Dermatitis, Solitary Fibrous Tumor, and Perniosis. Dr. Foss is currently accepting new patients.

 
 
 
 
Learn about our expert tiers
Learn More
Dr. Michael C. Margulies
Dermatology
Dr. Michael C. Margulies
Dermatology
8940 N Kendall Dr, Suite 704-e, 
Miami, FL 
 (187.7 mi)
305-595-0393
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Michael Margulies is a Dermatologist in Miami, Florida. Dr. Margulies and is rated as an Advanced provider by MediFind in the treatment of Dominant Dystrophic Epidermolysis Bullosa. His top areas of expertise are Rosacea, Candida Infection of the Skin, Epidermolysis Bullosa Simplex, and Dowling-Meara Epidermolysis Bullosa Simplex. Dr. Margulies is currently accepting new patients.

View All Doctors
What are the latest Dominant Dystrophic Epidermolysis Bullosa Clinical Trials?
EBULO. a 20-Week Multicentre, Open Study Assessing the Efficacy and Safety of Apremilast in Patients > 6 Years of Age with EB Simplex Generalized
EBULO. a 20-Week Multicentre, Open Study Assessing the Efficacy and Safety of Apremilast in Patients > 6 Years of Age with EB Simplex Generalized
Enrollment Status: Recruiting
Publish Date: February 24, 2025
Intervention Type: Drug
Study Phase: Phase 2

Summary: The goal of this clinical trial is to Assessing the Efficacy and Safety of Apremilast in Patients \> 6 years of age with EB simplex generalized . The main question it aims to answer are: describe efficacity of this treatment. Participants will take treatments and have to use bullets during the study period.

Match to trials
Find the right clinical trials for you in under a minute
Get started
A 44-week Monocentric Open Study Assessing the Efficacy and Safety of Deucravacitinib in Adults with Inflammatory Genodermatoses
A 44-week Monocentric Open Study Assessing the Efficacy and Safety of Deucravacitinib in Adults with Inflammatory Genodermatoses
Enrollment Status: Recruiting
Publish Date: February 24, 2025
Intervention Type: Drug
Study Phase: Phase 2

Summary: The goal of this clinical trial is to learn about deucravacitinib treatment in adults with inflammatory epidermal genodermatoses . The main question it aims to answer are: describe efficacity and safety of this treatment. Participants will take treatments and have to use bullets during the study period.

View All Clinical Trials
Who are the sources who wrote this article ?

Published Date: May 02, 2022
Published By: Genetic and Rare Diseases Informnation Center